1-20 of 27
Brian Higgins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3426: A synthetic lethality approach to eradicate AML via synergistic activation of pro-apoptotic p53 by MDM2 and BET inhibitors

Free
Sha Li, Anne Latif, Ashley Newcombe, Kathryn Gilroy, Neil Robertson, Xue Lei, Darren Finlay, Helen Stewart, Karina Barbosa, Brian Higgins, Tim Chevassut, Xu Huang, Mhairi Copland, Karen Keeshan, Ani Deshpande, Peter Adams
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3426.
https://doi.org/10.1158/1538-7445.AM2020-3426
Published: 15 August 2020
View articletitled, Abstract 3426: A synthetic lethality approach to eradicate AML via synergistic activation of pro-apoptotic p53 by MDM2 and BET inhibitors
Journal Articles

Abstract 513: The link between polyploidy and replication stress in melanoma

Free
Anna E. Vilgelm, C. Andrew Johnson, Kiran Malikayil, Dayanidhi Raman, David Flaherty, Brian Higgins, Ann Richmond
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 513.
https://doi.org/10.1158/1538-7445.AM2017-513
Published: 01 July 2017
View articletitled, Abstract 513: The link between polyploidy and replication stress in melanoma
Journal Articles

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Free
Christian Tovar, Bradford Graves, Kathryn Packman, Zoran Filipovic, Brian Higgins Mingxuan Xia, Christine Tardell, Rosario Garrido, Edmund Lee, Kenneth Kolinsky, Kwong-Him To, Michael Linn, Frank Podlaski, Peter Wovkulich, Binh Vu, Lyubomir T. Vassilev
Journal: Cancer Research
Cancer Res (2013) 73 (8): 2587–2597.
https://doi.org/10.1158/0008-5472.CAN-12-2807
Published: 15 April 2013
View articletitled, MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Open the PDF for MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models in another window
Includes: Supplementary data
Journal Articles

Abstract 4827: Humanized hepsin neutralizing antibody RO5486055 inhibits tumor growth and leads to accumulation of hepsin substrate laminin-332

Free
Sherif Daouti, Zoran Filipovic, Alvin Stern, Christine Tardell, Xiaolei Zhang, Debra Lucas-McGady, Brian Higgins, Kuo-Sen Huang, Ueli Gubler, Ying Li, Windy Berkofsky-Fessler, Julie Hang, Gennady Samokhin, Annette Seidl, Huifeng Niu, James Cai, Holly Hilton, Markus Thomas, Chandra Pamulapati, Olaf Mundigl, Silke Hansen, David C. Heimbrook, Kathryn E. Packman
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4827.
https://doi.org/10.1158/1538-7445.AM2012-4827
Published: 15 April 2012
View articletitled, Abstract 4827: Humanized hepsin neutralizing antibody RO5486055 inhibits tumor growth and leads to accumulation of hepsin substrate laminin-332
Journal Articles

Abstract 4727: Antitumor activity of the MDM2 antagonist, RG7112

Free
Christian Tovar, Zoran Filipovic, Thelma Thompson, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Dayanand Deo, Binh Vu, Bradford Graves, Lyubomir T. Vassilev
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4727.
https://doi.org/10.1158/1538-7445.AM2012-4727
Published: 15 April 2012
View articletitled, Abstract 4727: Antitumor activity of the MDM2 antagonist, RG7112
Journal Articles

Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer models

Free
Hong Yang, Brian Higgins, Kenneth Kolinsky, Jiakui Li, Richard Margolis, Zenaida Go, Aruna Railkar, Kathryn Packman, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2156.
https://doi.org/10.1158/1538-7445.AM2012-2156
Published: 15 April 2012
View articletitled, Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer models
Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Free
Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2012) 72 (4): 969–978.
https://doi.org/10.1158/0008-5472.CAN-11-1875
Published: 14 February 2012
View articletitled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Open the PDF for Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Free
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (3): 779–789.
https://doi.org/10.1158/0008-5472.CAN-11-2941
Published: 31 January 2012
View articletitled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Open the PDF for Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

Free
Huisheng Wang, Sherif Daouti, Wen-hui Li, Yang Wen, Christine Rizzo, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook, Huifeng Niu
Journal: Cancer Research
Cancer Res (2011) 71 (16): 5535–5545.
https://doi.org/10.1158/0008-5472.CAN-10-4351
Published: 11 August 2011
View articletitled, Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation
Open the PDF for Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation in another window
Includes: Supplementary data
Journal Articles

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Free
Brian Higgins, Kenneth Kolinksy, Zenaida Go, Hing Char, Richard Lee, Kathleen Schostack, Gideon Bollag, David Heimbrook, Fei Su, Kathryn E. Packman
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2562.
https://doi.org/10.1158/1538-7445.AM2011-2562
Published: 15 April 2011
View articletitled, Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model
Journal Articles

Abstract 5036: Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Free
Huifeng Niu, Huisheng Wang, Sherif Daouti, Wen-Hui Li, Yang Wen, Christine Rizzo, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5036.
https://doi.org/10.1158/1538-7445.AM2011-5036
Published: 15 April 2011
View articletitled, Abstract 5036: Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation
Journal Articles

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Free
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley Kolis, Sylvia Zhao, Richard Lee, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2010) 70 (13): 5518–5527.
https://doi.org/10.1158/0008-5472.CAN-10-0646
Published: 30 June 2010
View articletitled, RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Open the PDF for RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models in another window
Includes: Supplementary data
Journal Articles

Abstract 1370: RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo

Free
Christine Rizzo, Xuefeng Yin Yin, Kathryn Packman, Brian Higgins, Alfred Schnueriger, Markus Thomas, Michael Weidner, Dave Heimbrook, Mary Ellen C. Simcox
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1370.
https://doi.org/10.1158/1538-7445.AM10-1370
Published: 15 April 2010
View articletitled, Abstract 1370: RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo
Journal Articles

Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Free
Fei Su, Hong Yang, Brian Higgins, Kenneth Kolinsky, Richard Lee, Kathryn Packman, Kathleen Schostack, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4420.
Published: 01 May 2009
View articletitled, Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models
Journal Articles

Abstract #861: Activation of the p53 pathway by MDM2 antagonists enhances antitumor effect of androgen deprivation in prostate cancer cells

Free
Christan Tovar, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, David Heimbrook, Lyubomir Vassilev
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 861.
Published: 01 May 2009
View articletitled, Abstract #861: Activation of the p53 pathway by MDM2 antagonists enhances antitumor effect of androgen deprivation in prostate cancer cells
Journal Articles

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

Free
Sherif Daouti, Huisheng Wang, Wen-hui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Anthony Specian, Jr., Norman Kong, Nicholas Huby, Yang Wen, Qing Xiang, Frank J. Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu
Journal: Cancer Research
Cancer Res (2009) 69 (5): 1924–1932.
https://doi.org/10.1158/0008-5472.CAN-08-2627
Published: 02 March 2009
View articletitled, Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy
Open the PDF for Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy in another window
Includes: Supplementary data
Journal Articles

Breadth of activity of the tumor and angiogenesis inhibitor R1530 in human tumor xenograft models in nude mice

Free
Kenneth Kolinsky, Jianping Chen, Yu-E Zhang, Grace Ju, Kathryn Packman, Brian Higgins
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3995.
Published: 01 May 2007
View articletitled, Breadth of activity of the tumor and angiogenesis inhibitor R1530 in human tumor xenograft models in nude mice
Journal Articles

Preclinical dose and regimen optimization of the tumor and angiogenesis inhibitor R1530

Free
Kenneth Kolinsky, Yu-E Zhang, Thomas Nevins, Hong Yang, Wanping Geng, Martin Lamb, Peter Wovkulich, Grace Ju, Kathryn Packman, Brian Higgins
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3991.
Published: 01 May 2007
View articletitled, Preclinical dose and regimen optimization of the tumor and angiogenesis inhibitor R1530
Journal Articles

Antitumor mechanism of a novel tumor and angiogenesis inhibitor R1530

Free
Christian Tovar, Brian Higgins, David Heimbrook, Lyubomir Vassilev
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 5429.
Published: 01 May 2007
View articletitled, Antitumor mechanism of a novel tumor and angiogenesis inhibitor R1530
Journal Articles

Small-molecule inhibitors of the p53-MDM2 interaction

Free
Lyubomir Vassilev, Christian Tovar, Dejan Knezevic, Thelma Thompson, Zoran Filipovic, Brian Higgins, Weiguo Qing, Binh Vu, Frank Podlaski, Bradford Graves, David Heimbrook
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): SY13-02.
Published: 01 May 2007
View articletitled, Small-molecule inhibitors of the p53-MDM2 interaction